- Poster presentation
- Open Access
P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
Retrovirology volume 6, Article number: P197 (2009)
Induction and persistence of vaccine induced antibodies among recipients of HIV vaccines may pose a diagnostic challenge. We investigated the performance and usefulness of rapid tests for the detection of HIV antibodies among healthy HIV-uninfected people previously enrolled in a phase I HIV vaccine trial in Kigali, Rwanda.
Between September 2005 and May 2006, 57 healthy, HIV-uninfected adult volunteers (36 males and 21 females) were enrolled in a phase-I, randomized, placebo-controlled HIV vaccine trial at Projet San Francisco in Kigali, Rwanda. At the end of the trial and after unblinding, all volunteers were asked to participate in a long-term follow-up study for continuous clinical and immunological evaluation. HIV testing using three rapid tests (Abbott Determine™ HIV1-2, Trinity Biotech Capillus™ HIV-1/HIV-2 and Trinity Biotech Uni-GoldTM HIV) and an ELISA test (Bio-Mérieux Vironostika HIV Uniform II Ag/Ab) was performed every three months.
Of the 57 volunteers enrolled in the trial, 13 received placebo, 13 received one dose of a recombinant HIV-1 adenoviral type 5 vector vaccine (rAd5), and 31 received 3 doses of an HIV-1 DNA plasmid vaccine followed by one dose of rAd5. Of these 44 vaccine recipients, 41 produced HIV antibodies during the trial period. After 18 to 24 months of follow-up, 32 volunteers still test HIV-positive on the ELISA test, but only one volunteer tested persistently HIV positive using HIV rapid tests.
Most vaccine recipients produced HIV antibodies that have persisted for at least two years. These vaccine-induced antibodies are predominantly detected by a commercial ELISA test, and not by the three HIV rapid tests that were evaluated. This study suggests that HIV rapid tests can be very useful in the long-term follow-up of HIV vaccine recipients.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Karita, E., Kayitenkore, K., Bayingana, R. et al. P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients. Retrovirology 6 (Suppl 3), P197 (2009). https://doi.org/10.1186/1742-4690-6-S3-P197
- ELISA Test
- Rapid Test
- Adenoviral Type
- Vaccine Recipient
- Vector Vaccine